Literature DB >> 9196700

Anticoagulants for venous thrombosis.

C H Toh1.   

Abstract

The anticoagulant agents heparin and warfarin were introduced before the era of randomised clinical trials. As a result, the indications, dosages and monitoring techniques of these drugs have undergone re-evaluation in multiple clinical trials in the past years. Low molecular weight heparin has been developed, which has led to new approaches in anticoagulant management. Current levels of laboratory, pharmacology and clinical knowledge in the treatment of venous thromboembolism are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196700      PMCID: PMC2431305          DOI: 10.1136/pgmj.73.859.283

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

1.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

2.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

3.  Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.

Authors:  T Mätzsch; D Bergqvist; U Hedner; P Ostergaard
Journal:  Thromb Haemost       Date:  1987-02-03       Impact factor: 5.249

4.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; A A Panju; P Brill-Edwards; J S Ginsberg; J Hirsh; G J Martin; D Green
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

5.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; G F Pineo; D Green; A A Trowbridge; C G Elliott; R G Lerner; J Hall; T Sparling; H R Brettell
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

6.  Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism.

Authors:  S M Mohiuddin; D E Hilleman; C J Destache; A M Stoysich; J M Gannon; M H Sketch
Journal:  Am Heart J       Date:  1992-03       Impact factor: 4.749

7.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

9.  Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

Authors:  A Gallus; J Jackaman; J Tillett; W Mills; A Wycherley
Journal:  Lancet       Date:  1986-12-06       Impact factor: 79.321

Review 10.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

View more
  1 in total

1.  Anticoagulants for venous thrombosis.

Authors:  C Borland; C Wilkinson; K Hogarth
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.